Companies › AskGene Pharma
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ASKB589 | – | Phase 3 | Gastroesophageal Junction Adenocarcinoma; Gastric Cancer | Dec 2026 |
| ASKG915 | – | Phase 1 | Advanced Solid Tumors | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05632939 | ASKB589 | Phase 1 | Gastric Cancer | Oncology | Oct 2025 |
| NCT06206733 | ASKB589 | Phase 3 | Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2026 |
| NCT05867420 | ASKG915 | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2026 |
No annotated target.
–
Lepu Biopharma Coherus Oncology OncoC4 Tesaro GC Cell
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.